Effect of Sildenafil Drug on Treatment of patient with Idiopathic Pulmonary Hypertension
Keywords:
Sildenafil, a pulmonary vasodilator, pulmonary hypertensionAbstract
Background: Primary pulmonary hypertension (PPH) is a disorder intrinsic to the pulmonary vascular bed that is characterized by sustained elevations in pulmonary artery pressure (PAP) and vascular resistance that generally lead to right ventricle (RV) failure and death.
Objective: To assess the effect of sildenafil drug on treatment of patient with idiopathic pulmonary hypertension.
Patients and method: Forty patients (30 females and 10 males) with IPH were included in this study .The study was conducted in ibn Al-Betar cardiac surgery center in Baghdad and conducted between Jan.2007 to Jul.2008.All patients had been followed for three months. Any patient with IPH at any New York heart association functional class(NYHA FC) who can tolerate Sildenafil and has no contra indication to it, whether on anticoagulation, digoxin and diuretics or not.
Results: no statistically significant relationship between gender, age and duration of symptoms and response of NYHA FC to Sildenafil therapy. while the NYHA FC had significant relationship with NYHA FC improvement after Sildenafil therapy. The difference was highly significant (P=0.0001) using t-test for two dependent means according to PASP measurements pre and post treatment of PPH patients included in the study.
Conclusion: Sildenafil, a pulmonary vasodilator, improves NYHA FC and decreases PASP in patients with idiopathic pulmonary hypertension.
Downloads
References
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, Levy PC. Primary pulmonary hypertension: a national prospective study. Annals of internal medicine. 1987 Aug 1;107(2):216-23.
Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RM, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society for Heart and Lung Transplantation (ISHLT) and the European Reference Network on rare respiratory diseases (ERN-LUNG). European heart journal. 2022 Oct 7;43(38):3618-731.
Bachinskaia EN, Nonikov VE. Diagnosis and treatment of pulmonary hypertension: current concepts. Kardiologiia. 2005 Jan 1;45(6):81-6.
Klings ES, Farber HW. Current managementof PPH. Drugs.2001;61:1945–56.
Rubin LJ. Primary pulmonary hypertension.N Engl J Med. 1997;336:111–7.
Guazzi M, Arena R. Pulmonary hypertension with left-sided heart disease. Nature Reviews Cardiology. 2010 Nov;7(11):648-59.
Nichols WC, Koller DL, Slovis B, Foroud T, Terry VH, Arnold ND, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32. Nature genetics. 1997 Mar 1;15(3):277-80.
Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, Nichols WC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nature genetics. 2000 Sep;26(1):81-4.
Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (Gene PPH1) is caused by mutations in the bone morphogenetic protein receptor–II gene. The American Journal of Human Genetics. 2000 Sep 1;67(3):737-44.
Galiè N, Humbert M, Vachiéry JL, Vizza C, Kneussl M, Manes A, Sitbon O, Torbicki A, Delcroix M, Naeije R, Hoeper M. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. Journal of the American College of Cardiology. 2002 May 1;39(9):1496-502.
Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvascular research. 2004 Sep 1;68(2):75-103.
Nagayama T, Hsu S, Zhang M, Koitabashi N, Bedja D, Gabrielson KL, Takimoto E, Kass DA. Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload. Journal of the American College of Cardiology. 2009 Jan 13;53(2):207-15.
Abdelhady K, Gramling-Babb P, Awad S, Rebeiz AG, Salehi P, Chaudhry A, Diodato M, Rizkallah LE, Chedrawy EG, Prasad S, Massad MG. Current and future therapy for pulmonary hypertension in patients with right and left heart failure. Expert Review of Cardiovascular Therapy. 2010 Feb 1;8(2):241-50.
Guglin M, Rajagopalan N, Anaya P, Charnigo R. Sildenafil in heart failure with reactive pulmonary hypertension (Sildenafil HF) clinical trial (rationale and design). Pulmonary Circulation. 2016 Jun;6(2):161-7.
Gerhardt F, Dumitrescu D, Gärtner C, Beccard R, Viethen T, Kramer T, Baldus S, Hellmich M, Schönau E, Rosenkranz S. Oscillatory whole-body vibration improves exercise capacity and physical performance in pulmonary arterial hypertension: a randomised clinical study. Heart. 2017 Apr 1;103(8):592-8.
